简而言之，BLD1102 是百奥赛图自主开发的新型ADC平台。
作为百奥赛图“千鼠万抗”（RenBiologics）的一部分，来自RenLite小鼠的全人TAA靶向抗体组合将被组装并在体内评估其药理疗效，同时还将进行体外分析。公司构建的大动物转化平台将进一步筛选出具有更佳转化特性的产品。
| Target(s) | Immunization |
|
CMC | Nonclinical | Phase I | Status |
| TROP2 x EGFR |
|
Partnered | ||||
| EGFR x MET |
|
Partnered | ||||
| HER3 x MUC1 |
|
Partnered | ||||
| HER2 x TROP2 |
|
Partnered | ||||
| EGFR x MUC1 |
|
Partnered | ||||
| PTK7 x B7-H3 |
|
Partnered | ||||
| EGFR x HER3 |
|
Partnered | ||||
| PTK7 x EGFR |
|
|||||
| PTK7 x TROP2 |
|
|||||
| SEZ6 x B7-H3 |
|
Partnered | ||||
| HER3 x MET |
|
|||||
| HER3 x B7-H3 |
|
|||||
| DLL3 x B7-H3 |
|
|||||
| DLL3 x SEZ6 |
|
|||||
| FOLR1 x FOLR1 |
|
|||||
| MUC1 x TROP2 |
|
|||||
| FOLR1 x MUC1 |
|
|||||
| ITGB6 x B7-H3 |
|
|||||
| FOLR1 x MUC16 |
|
|||||
| HER3 x EPCAM |
|
|||||
| EGFR x 5T4 (TPBG) |
|
|||||
| 5T4 (TPBG) x MUC1 |
|
|||||
| TROP2 x NECTIN-4 |
|
|||||
| FAP x GPC1 |
|
|||||
| MET x B7-H3 |
|
|||||
| MET x EPCAM |
|
|||||
| MSLN x MSLN |
|
|||||
| LGR5 x EGFR |
|
|||||
| CDH6 x FOLR1 |
|
|||||
| MSLN x FOLR1 |
|
|||||
| MSLN x MUC1 |
|
|||||
| FAP x B7-H3 |
|
|||||
| FAP x TROP2 |
|
|||||
| FAP x CDCP1 |
|
|||||
| CDH17 x Claudin 18.2 |
|
|||||
| CDH17 x MET |
|
|||||
